Study overturns century-old rule of pharmacology

One of pharmacology's oldest underlying principles looks set to be overturned. New findings from chemists at the UK's University of Warwick appear to contradict the century-old 'Overton's Rule', which sets out how fast chemicals, such as medicines, can cross cell walls. The findings have major implications for drug development.

Many drugs need to get inside our cells to work effectively. While some molecules gain entry to the cell actively, via special structures embedded in the cell membrane, others gain access passively by permeating the cell's lipid membrane. Overton's Rule concerns molecules that get into cells via passive permeation.

Back in the 1890s, Swiss scientist Ernst Overton developed an equation which predicts how long it should take a given molecule to enter a cell. The resulting rule, which was named after its inventor, states that the easier it is for a chemical to dissolve in a lipid (fat), the faster it will be transported into a cell. One of the most important parameters in Overton's Rule is K, which defines the lipophilicity (oil-liking nature) of the chemical under investigation. The higher the value of K, the faster the rate of diffusion across the cell membrane. In other words, the more lipid-loving a chemical is, the faster it will get into a cell. In the century since Dr Overton first came up with his equation, medicinal scientists have relied on Overton's Rule when designing studies and clinical trials.

In this recent piece of research, the scientists used the latest technology to study in great detail exactly what happens when a molecule enters a cell. They used weak acids for their study; according to Overton's rule, these lipophilic molecules should cross the cell membrane relatively quickly. Their results are published online in the Proceedings of the National Academy of Sciences (PNAS).

What they observed shocked the researchers. Their results flew in the face of accepted wisdom and directly contradicted Overton's Rule. In short, the most lipophilic molecules took the longest to cross the membrane, and the least lipophilic acids were the fastest. The new rule suggests that Overton's Rule needs to be turned on its head; according to these results, the easier it is for a chemical to dissolve in a lipid, the slower it is transported across the cell membrane.

"This was a surprising and exciting finding. Our direct observations appear to totally undermine a key rule that has withstood the test of time for over a century," said lead researcher Professor Patrick Unwin.

"We will now make observations with a range of other chemicals, and with other techniques, to further elucidate the molecular basis for our observations. Text books will have to be rewritten to revise a rule that has been relied on for over a century. Advanced techniques, such as the one we have developed, should give much clearer insight into the action of a wide range of drug molecules, which will be of significant interest to drug developers."

For further information, please visit:

University of Warwick
http://www.warwick.ac.uk

Proceedings of the National Academy of Sciences (PNAS)
http://www.pnas.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Sanofi to provide manufacturing support to Johnson…

Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, u...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

Sanofi and GSK initiate new Phase 2 study of their…

Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Ph...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...